
Weight-loss jabs for children ‘are effective and help prevent mealtime battles'
Experts at the European Congress on Obesity in Malaga, Spain, presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and lifestyle plan they were already following.
Weight-loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings and are available on the NHS for adults with a high body mass index (BMI), or via private providers.
The National Institute for Health and Care Excellence (Nice) stopped its appraisal of semaglutide (Wegovy) for managing obesity in children aged 12 to 17 after the manufacturer, Novo Nordisk, said it was unable to provide an evidence submission.
However, specialist paediatric clinics can prescribe weight-loss injections if there is a proven clinical need.
Side-effects of weight-loss drugs include nausea, diarrhoea, stomach cramps and vision problems.
Dr Annika Janson, from Karolinska University Hospital in Sweden – who presented the new research, said: 'GLP-1 drugs are increasingly used to treat obesity in adults.
'They can also be used in children from the age of 12 and clinical trials have shown children lose 5%-16% of their body weight after a year of treatment.
'However, treating children in real-life situations has challenges that don't come up in research studies.
'Children have varying degrees of obesity, co-morbidities and complications and may have faced problems in supply of the drug, financing it or taking it.
'As a consequence, it is difficult to isolate the effect of adding GLP-1 drugs to the plethora of treatments that are already available.'
To address this question, Dr Janson and colleagues added GLP-1 receptor agonists to an existing treatment programme for child obesity.
The study involved 1,126 children (52% of them boys) aged up to 16 with severe obesity who were receiving intensive health behaviour and lifestyle treatment (IHBLT) at the National Childhood Obesity Centre in Stockholm.
IHBLT involves working with children, families and schools and looks at healthy foods, meal size, meal order, screen time, exercise and psychological wellbeing.
From 2023, GLP-1 drug liraglutide was included for around one in four patients. Later on, the drug semaglutide (Wegovy) was used.
While the reduction in BMI was similar between the groups until 2022, adding a weight loss jab had an additional effect.
Some 30% on liraglutide dropped enough weight to improve their health, compared with around 27% of those treated earlier on with no jab.
While the differences do not seem big, and not all children were taking the drug at all points, it suggests a trend, Dr Janson said. She said there were better later results with semaglutide.
'Only a fraction of the children had GLP-1 drugs and most of those who did started on them six to 12 months into the treatment programme. Longer-term treatment may lead to greater improvements in BMI,' she said.
'These are just early indications but it does look as if the average effect of being a patient at our clinic has improved after adding GLP-1 drugs to the toolbox.'
She added: 'Many children with severe obesity describe hunger and a strong appetite – both of which GLP-1 receptor agonists are known to help with.
'Results beyond obesity are also important. The families reported reduced conflicts around food and improved capacity for other lifestyle adaptations.
'It was easier to stick to meals and limit snacks. Portions could be down-sized. For some children, not being hungry all the time is a new feeling.
'GLP-1 receptor agonists are clearly beneficial to many children with severe obesity and, while they won't help in all cases, more children should have access to these important medications.'
A spokesman for Novo Nordisk said: 'Novo Nordisk did not submit evidence for a Nice appraisal for semaglutide and liraglutide for managing overweight and obesity in young people aged 12 to 17 years due to a lack of utility data and risk equations in linking weight loss in adolescents to long-term outcomes.
'As such, there are significant limitations in estimating the cost-effectiveness in this patient population, utility estimates that adequately capture the full impact on their quality of life, and not enough data to support an economic model that meets the Nice reference case.
'At this time, Novo Nordisk does not intend to make an evidence submission for the appraisal of semaglutide and liraglutide for managing overweight and obesity in young people aged 12 to 17 for the use in the NHS.
'We will continue to evaluate our evidence package in consideration of supporting any potential future submission for this patient group.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medical News Today
14 minutes ago
- Medical News Today
Contrave vs. Wegovy: What to know about each
Contrave (naltrexone/bupropion) and Wegovy (semaglutide) are brand-name drugs. They're both prescribed for weight loss in adults. This article explains the main similarities and differences between Contrave and Wegovy. If you're considering taking one of these drugs, discussing this information with your doctor can help you decide whether one of these treatments may be right for you. Note: For more comprehensive information about these two drugs, you can refer to our Contrave and Wegovy articles. These are a few of the main differences between Contrave and Wegovy: Form: Contrave comes as an extended-release oral tablet, while Wegovy is a solution in prefilled, single-use pens that administer the medication as a subcutaneous injection. ('Extended-release' means the drug slowly releases into your body over a long period of time.) Contrave comes as an extended-release oral tablet, while Wegovy is a solution in prefilled, single-use pens that administer the medication as a subcutaneous injection. ('Extended-release' means the drug slowly releases into your body over a long period of time.) Dosage : Contrave is taken more often than Wegovy. (See the Dosage section.) : Contrave is taken more often than Wegovy. (See the Dosage section.) Conditions treated: Contrave and Wegovy are both used for weight loss in certain adults, but Wegovy is also used for weight management in certain children and to lower certain cardiovascular risks in certain adults. (See the Uses section.) Contrave and Wegovy have been approved by the Food and Drug Administration (FDA) for the following uses in adults, in combination with exercise and a reduced-calorie diet. Contrave and Wegovy are FDA approved for: Wegovy is also FDA approved to: lower the risk of serious cardiovascular (heart and blood vessel) events, including non-fatal heart attack or stroke, in adults with cardiovascular disease, or who have obesity or are considered overweight Wegovy is approved for weight loss and management in children ages 12 years and older with obesity, usually defined as a BMI of 30 kg/m2 or greater. Contrave is not approved for use in children. The medication has a boxed warning that includes a note that it has not been studied in children. To learn more about this warning, see 'Precautions for Contrave and Wegovy'. Note: For more information about the drugs' uses, see our articles about Contrave and Wegovy. Here's a quick look at the dosage and administration of Contrave and Wegovy for the conditions they treat. Below is information on Contrave and Wegovy dosages for weight management in adults. Wegovy comes as a solution inside prefilled, single-use pens given as a subcutaneous injection. When you're first prescribed Wegovy, a healthcare professional will show you how to give yourself the injections. You can also refer to the 'How to Take Wegovy' guide from the manufacturer. Note: For more information about dosage, see our dosage articles about Contrave and Wegovy. Contrave and Wegovy are both used for weight management in certain adults. These drugs can cause some of the same side effects, as well as different ones. Some of the side effects reported in clinical trials of these drugs are listed here. The following table lists some of the more commonly reported mild side effects of Contrave and Wegovy. The table may also include mild side effects that are less common, but you may have concerns about them in some cases. These side effects may be temporary, lasting a few days to weeks. If the side effects last longer than that, bother you, or become severe, be sure to talk with your doctor or pharmacist. The following table lists reported serious side effects of Contrave and Wegovy. If you have serious side effects while using Contrave or Wegovy, call your doctor immediately. If the side effects feel life threatening or you believe you're having a medical emergency, call 911 or your local emergency number right away. * Contrave has a boxed warning for this side effect. A boxed warning is a serious warning from the FDA. To learn more, see the 'Precautions for Contrave and Wegovy' section. ** Wegovy has a boxed warning for this side effect. A boxed warning is a serious warning from the FDA. To learn more, see the 'Precautions for Contrave and Wegovy' section. ALLERGIC REACTION For some people, Contrave and Wegovy can cause an allergic reaction. In general, symptoms of an allergic reaction can be mild or serious. Ways to manage For mild allergic reaction symptoms, such as a mild rash, call your doctor right away. They may recommend treatments to help manage your symptoms. They'll also let you know whether you should keep taking the medication. For severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms require immediate medical care because they can become life threatening. If you've had a serious allergic reaction to Contrave, your doctor may recommend taking a different medication instead. Here are answers to some common questions about Contrave and Wegovy. It's not clear. Currently, there aren't enough studies evaluating whether it's safe to take Contrave and Wegovy for weight loss together or if taking them together is more effective for weight loss and management than taking either medication on their own. In fact, the prescribing information for Contrave specifically notes that it hasn't been studied in combination with other medications for weight loss. Due to the lack of evidence, your doctor may not prescribe Contrave and Wegovy together. Contrave and Wegovy can cause some similar side effects, including increased heart rate. Taking them together may further raise your risk for certain side effects caused by both medications. Talk with your doctor if you're thinking about taking Wegovy or Contrave for weight loss. They can help determine the best treatment plan for you. You may wonder how Wegovy and Contrave compare to Ozempic, Qsymia, Saxenda, and similar medications. The table below includes a few key details on how Contrave and Wegovy compare to similar drugs. It's important to note that some of these drugs are approved for different uses. Your doctor can help determine which of these medications is the best fit for you based on your treatment needs. Contrave and Wegovy are both FDA approved for: weight loss and management, in adults with a BMI of 30 kg/m 2 or greater, which indicates obesity or greater, which indicates obesity weight loss and management, in adults with a BMI of 27 kg/m2 or greater (which is considered overweight) who also have at least one weight-related condition, including high blood pressure, high cholesterol, or type 2 diabetes If you're considering treatment with either medication for these uses, you may wonder how their effectiveness compares. Prescribing information: Both Contrave and Wegovy were found to be effective for weight loss and management in certain adults in clinical trials. For details about how these drugs performed in clinical trials, see the prescribing information for Contrave and Wegovy. Keep in mind that trial results may not apply to your individual health situation. Treatment guidelines: Another way to determine whether a drug is considered effective is to look at treatment guidelines. When an organization includes certain drugs in treatment guidelines, this means research has shown the drug to be safe and effective. Both Contrave and Wegovy are recommended as a treatment option for weight loss and management in certain adults in guidelines from the American Gastroenterological Association. How much Contrave or Wegovy costs depends on the treatment plan your doctor prescribes, your insurance plan, and your pharmacy. You can visit Optum Perks for price estimates of Contrave and Wegovy. (Optum Perks is a sister site of Medical News Today.) Both Contrave and Wegovy are brand-name drugs. Neither Contrave nor Wegovy is available in a generic form. Brand-name medications often cost more than generics. Talk with your doctor or pharmacist to learn about the generic form of either drug. Contrave and Wegovy may not be right for you if you have certain medical conditions or other factors that affect your health. These drugs have some of the same precautions, but they also have different ones. Some of these precautions are mentioned here. Wegovy has a boxed warning for the risk of thyroid cancer. A boxed warning is a serious warning from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous. During treatment with Wegovy, let your doctor know if you have symptoms of thyroid tumors or cancer. Examples include a hoarse voice that doesn't go away, a mass or lump in your neck, and shortness of breath. Contrave has a boxed warning about the risk for suicidal thoughts and behaviors. Risk for suicidal thoughts and behaviors: Contrave contains bupropion as one of its active ingredients (what makes a drug work). Bupropion is an antidepressant, and antidepressants may cause a small increase in risk for suicidal thoughts and behaviors. This risk applies to children and adults ages 24 and under, based on a large review of studies evaluating short-term antidepressant use. It's important to note that Contrave is not approved for use in children. Contrave is also not approved for treating depression or any other mental health condition. In addition to boxed warnings, Contrave and Wegovy have other warnings. If any of the following medical conditions or other health factors are relevant to you, talk with your doctor before using Contrave or Wegovy. Note: For more comprehensive information about these drugs, you can refer to our Contrave and Wegovy articles. Switching between Contrave and Wegovy might be possible. Both Contrave and Wegovy are approved for weight loss and management, along with diet and exercise, in certain adults. If you're taking Wegovy to lower your risk for certain cardiovascular problems, your doctor likely will not switch you to Contrave for this use. This isn't an approved use for Contrave. If you'd like to know more about switching between Contrave and Wegovy, talk with your doctor. They can give you additional details and help determine the best course of action for your personal situation. Even if two drugs treat the same condition or are in the same drug class, your body can still respond differently. It's important that you do not stop, start, or switch any of your drug treatments without your doctor's recommendation. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.


Daily Record
21 minutes ago
- Daily Record
Scots man who collapsed in Florida may never walk again if family can't bring him home
Gordon Milloy suffered heart and kidney failure, which triggered multiple strokes. His brother Brian found him fighting for his life on his bathroom floor. A carpenter who collapsed on a bathroom floor in Florida may never walk again and be ' bedridden for life' if he doesn't get home to Scotland. Gordon Milloy, from Kilmarnock, now lives in Fort Lauderdale and suffered heart and kidney failure, which triggered multiple strokes on Tuesday, March 4. The 50-year-old is now stuck in the US in HCA Florida JFK Hospital as his family battle to bring him home to Scotland for treatment. He has a health insurance policy with the Florida Blue, who have offered to place Gordon in a Skilled Nursing Facility (SNF). However, his brother Brian Milloy, 57, believes that a Acute Rehabilitation Facility (IRF) will be more effective in getting him back on his feet. SNF is usually offered to patients who are too weak or unstable to tolerate intensive therapy and can act as an intermediate option before going forward with IRF. Brian said: 'The insurance company is denying him access to acute rehabilitation claiming he's not fit enough to complete it - despite doctors saying he's ready to be discharged. "They are offering Skilled Nursing. It is proving very difficult to find a SNF with dialysis on hand - which he currently requires three times per week as his liver function is still in the balance. "In Scotland, Gordon will be offered IRF. We need to get him back home. "Without acute rehab and specialised equipment, he'll likely remain bedridden for the rest of his life. He will basically have no life at all." His brother Brian also lives in Florida and found Gordon collapsed and clinging to life in his home in early March. He said: 'Gordon was lying collapsed on the bathroom floor. He had heart and kidney failure which had caused multiple strokes. The doctors reckon his heart was only functioning at 20% at one point.' Gordon's family now hope to get him back to Scotland where he can get access to NHS care and receive the treatment he needs. Brian added: "For him to have any sort of life, he needs to be home in Scotland where he has access to the NHS. It is very doubtful that he'll ever be able to work again either. He won't be able to support himself financially in the US. "We need to get him back to Scotland where he'll receive dialysis, post-stroke care and acute rehabilitation. It would be better all round." The cost to fly Gordon home through a US medical flights is believed to be around £300,000. Companies in the UK also quoted the family around £100,000 to £150,000. The family has now found a German firm partnered with Lufthansa, AirAmbulance24, who offered the flight, complete with a stretcher, medical team, and ground transport, for just under £50,000. Now, Brian has launched a GoFundMe, which has already raised over nearly £21,000, in a desperate bid to raise the funds. 'I'm reaching out to anyone who can help get my brother Gordy back to Scotland for the proper care required to hopefully live a somewhat normal life again,' he said. 'We just want him home. He deserves a chance. He's a gentle giant who's been through hell.' To support the Milloy family's fight to bring Gordon home, visit their GoFundMe page - Florida Blue were approached for comment but said they couldn't comment on individual cases. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'.


Daily Mirror
an hour ago
- Daily Mirror
NHS chief gives verdict on funding settlement outlined in spending review
New NHS England boss Sir Jim Mackey insists the NHS has done "really well" in the spending review - despite a lower rate of increase than under the Tories in 2023 The new boss of the NHS has said the health service has done 'really well' out of the spending review - despite getting a worse funding settlement than under the Tories. Sir Jim Mackey gave his first major speech at the annual NHS Confed Expo conference in Manchester moments before Chancellor Rachel Reeves confirmed the health service will get a major funding squeeze. The Chancellor's spending review will mean a 3% annual budget rise, which is lower than the average 3.6% increases the NHS has received since its founding. It is also lower than the 3.3% rise seen in 2023 under the previous Conservative governments. But Sir Jim told health leaders: "The NHS has done really well relative to other parts of the public service but we all know it's never enough because of the scale of advancement, all the ambition, all things we want to do, the day-to-day cost pressures we're trying to get on top of, etc. "We're always going to be in a world where we want more money, but I think everyone's starting to accept and understand that we've got what the country can afford to give us. We really need to get better value for that money - it is broadly the equivalent of the GDP of Portugal, so it's a huge amount of money by any standards. "It's a huge amount - (the) Government has done us a really good turn compared to other parts of the public service. But it's not going to allow us all to just take our feet off the pedal and just run loose and do what we want to do in this next period, we have still got an awful lot of difficult things to do." Sir Jim succeeded previous chief executive Amanda Pritchard as the Government took direct control of NHS England, which had previously been operationally independent. Chancellor Rachel Reeves delivered her Spending Review, setting out budgets for government departments. She said she has made "tough decisions" but is rejecting "austerity". Healthcare spending generally increases to keep pace with a growing and aging population. The UK spends less on healthcare than most other European countries. The 3% rise will add up to about £30 billion a year extra by the end of the parliament. It comes as the NHS is likely to have to find the cash for above-inflation pay rises for staff and a large chunk of a £1 billion-a-year rise in drug prices ministers have promised to the pharmaceutical industry. Sir Jim acknowledged it will be a struggle for the NHS to improve 'delayed discharges' where hospitals are full of frail but otherwise well people because there is no social care places for them. He added: "Social care in local authorities won't do brilliantly in the spending review… so we will be left with what we can do as much as we can within our gift." It comes as internal Government modelling suggests that without more NHS funding Sir Keir Starmer 's government will miss a key pledge to treat 92% of patients requiring routine care within 18 weeks. The NHS constitutional standard has not been met for a decade. Sally Gainsbury, of the Nuffield Trust think tank, told the Times that "an extra 2.8 per cent in real terms will not fully cover the new demands the health service can expect each year, let alone eliminate previous problems like the waiting list backlog".